04 February 2019 by Djuro Kosanovic

FasL is a potential circulating biomarker during acute and chronic exposure to high altitude in Kyrgyz population

Background - Abnormally regulated apoptosis and circulating apoptotic signal, such as pro-apoptotic mediator Fas ligand (FasL), were found in several pathologies, including heart disorders, cancer and pulmonary hypertension (PH). Yet, almost nothing is known about the expression profile and biomarker properties of FasL in the circulation of human beings during acute and chronic exposure to high altitude (HA) environment.

Methods - In order to investigate the presence and potential biomarker attributes of FasL, we have measured the plasma values of FasL using enzyme-linked immunosorbent assay in Kyrgyz volunteers exposed to acute (n=7-8) and chronic effects (n=9-10) of HA milieu.

Results - We have found that there was a prominent reduction of FasL in the blood of lowland subjects exposed to HA environment. In addition, decreased circulatory levels of FasL were demonstrated in highlanders with HA-induced PH (HAPH), in comparison to the lowland controls. Finally, there was a negative correlation between the FasL concentration in plasma and tricuspid regurgitant gradient values.

Conclusion - Therefore, we have described for the first time that circulating levels of FasL were decreased in human subjects exposed to acute and chronic effects of HA environment. Furthermore, FasL may serve as a promising biomarker in the future for patients with HAPH.

About the author


profile picture of Djuro Kosanovic

Djuro Kosanovic

PhD

Justus-Liebig University; Universities of Giessen and Marburg Lung Cen...

Germany

"PVRI is not only the leading medical and scientific research umbrella in the field of pulmonary vascular disease, but it also provides organizes and controls indispensable activities with regard to the education and training of younger professionals. It also represents a platform for exposure of different (and sometimes controversial) ideas, philosophy and concepts."

Key Contributors

Djuro Kosanovic1, Simon Maximilian Platzek1, Aleksandar Petrovic1, Akylbek Sydykov1, Abdirashit Maripov2, Argen Mamazhakypov1, Meerim Sartmyrzaeva2, Kubatbek Muratali Uulu2, Meerim Cholponbaeva2, Aidana Toktosunova2, Nazgul Omurzakova2, Melis Duishobaev2, Christina Vroom1, Oleg Pak1, Norbert Weissmann1, Hossein Ardeschir Ghofrani1, Akpay Sarybaev2, Ralph Theo Schermuly1 1Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany 2Kyrgyz National Centre for Cardiology and Internal Medicine (NCCIM), named after academician Mirsaid Mirrakhimov, Bishkek, Kyrgyzstan


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg